Refine
Is part of the Bibliography
- yes (13)
Keywords
- Aphid host (2)
- Aphidius ervi (2)
- Chemosensory genes (2)
- DNA methylation loss (2)
- GC content (2)
- Lysiphlebus fabarum (2)
- Parasitoid wasp (2)
- Toll and Imd pathways (2)
- Venom proteins (2)
- acute kidney injury (2)
- de novo genome assembly (2)
- end-stage kidney disease (2)
- genome-wide association (2)
- rapid eGFRcrea decline (2)
- study (2)
- Childhood traits and disorders (1)
- Community-based modelling (1)
- Consortium (1)
- DATM (1)
- Database approach to modelling (1)
- Differential equation (1)
- Galaxy: general (1)
- Galaxy: stellar content (1)
- Galaxy: structure (1)
- Genetics (1)
- Longitudinal (1)
- Modelling framework (1)
- Programming language (1)
- biomarker (1)
- canine osteoarthritis (1)
- extra-cellular matrix (1)
- proteomix analysis (1)
- stars: distances (1)
- stars: fundamental parameters (1)
- synovial fluid (1)
We present a catalogue of 362 million stellar parameters, distances, and extinctions derived from Gaia's Early Data Release (EDR3) cross-matched with the photometric catalogues of Pan-STARRS1, SkyMapper, 2MASS, and All WISE. The higher precision of the Gaia EDR3 data, combined with the broad wavelength coverage of the additional photometric surveys and the new stellar-density priors of the StarHorse code, allows us to substantially improve the accuracy and precision over previous photo-astrometric stellar-parameter estimates. At magnitude G = 14 (17), our typical precisions amount to 3% (15%) in distance, 0.13 mag (0.15 mag) in V-band extinction, and 140 K (180 K) in effective temperature. Our results are validated by comparisons with open clusters, as well as with asteroseismic and spectroscopic measurements, indicating systematic errors smaller than the nominal uncertainties for the vast majority of objects. We also provide distance- and extinction-corrected colour-magnitude diagrams, extinction maps, and extensive stellar density maps that reveal detailed substructures in the Milky Way and beyond. The new density maps now probe a much greater volume, extending to regions beyond the Galactic bar and to Local Group galaxies, with a larger total number density. We publish our results through an ADQL query interface (gaia . aip . de) as well as via tables containing approximations of the full posterior distributions. Our multi-wavelength approach and the deep magnitude limit render our results useful also beyond the next Gaia release, DR3.
Rapid decline of glomerular filtration rate estimated from creatinine (eGFRcrea) is associated with severe clinical endpoints. In contrast to cross-sectionally assessed eGFRcrea, the genetic basis for rapid eGFRcrea decline is largely unknown. To help define this, we meta-analyzed 42 genome-wide association studies from the Chronic Kidney Diseases Genetics Consortium and United Kingdom Biobank to identify genetic loci for rapid eGFRcrea decline. Two definitions of eGFRcrea decline were used: 3 mL/min/1.73m(2)/year or more ("Rapid3"; encompassing 34,874 cases, 107,090 controls) and eGFRcrea decline 25% or more and eGFRcrea under 60 mL/min/1.73m(2) at follow-up among those with eGFRcrea 60 mL/min/1.73m(2) or more at baseline ("CKDi25"; encompassing 19,901 cases, 175,244 controls). Seven independent variants were identified across six loci for Rapid3 and/or CKDi25: consisting of five variants at four loci with genome-wide significance (near UMOD-PDILT (2), PRKAG2, WDR72, OR2S2) and two variants among 265 known eGFRcrea variants (near GATM, LARP4B). All these loci were novel for Rapid3 and/or CKDi25 and our bioinformatic follow-up prioritized variants and genes underneath these loci. The OR2S2 locus is novel for any eGFRcrea trait including interesting candidates. For the five genome-wide significant lead variants, we found supporting effects for annual change in blood urea nitrogen or cystatin-based eGFR, but not for GATM or (LARP4B). Individuals at high compared to those at low genetic risk (8-14 vs. 0-5 adverse alleles) had a 1.20-fold increased risk of acute kidney injury (95% confidence interval 1.08-1.33). Thus, our identified loci for rapid kidney function decline may help prioritize therapeutic targets and identify mechanisms and individuals at risk for sustained deterioration of kidney function.
Rapid decline of glomerular filtration rate estimated from creatinine (eGFRcrea) is associated with severe clinical endpoints. In contrast to cross-sectionally assessed eGFRcrea, the genetic basis for rapid eGFRcrea decline is largely unknown. To help define this, we meta-analyzed 42 genome-wide association studies from the Chronic Kidney Diseases Genetics Consortium and United Kingdom Biobank to identify genetic loci for rapid eGFRcrea decline. Two definitions of eGFRcrea decline were used: 3 mL/min/1.73m(2)/year or more ("Rapid3"; encompassing 34,874 cases, 107,090 controls) and eGFRcrea decline 25% or more and eGFRcrea under 60 mL/min/1.73m(2) at follow-up among those with eGFRcrea 60 mL/min/1.73m(2) or more at baseline ("CKDi25"; encompassing 19,901 cases, 175,244 controls). Seven independent variants were identified across six loci for Rapid3 and/or CKDi25: consisting of five variants at four loci with genome-wide significance (near UMOD-PDILT (2), PRKAG2, WDR72, OR2S2) and two variants among 265 known eGFRcrea variants (near GATM, LARP4B). All these loci were novel for Rapid3 and/or CKDi25 and our bioinformatic follow-up prioritized variants and genes underneath these loci. The OR2S2 locus is novel for any eGFRcrea trait including interesting candidates. For the five genome-wide significant lead variants, we found supporting effects for annual change in blood urea nitrogen or cystatin-based eGFR, but not for GATM or (LARP4B). Individuals at high compared to those at low genetic risk (8-14 vs. 0-5 adverse alleles) had a 1.20-fold increased risk of acute kidney injury (95% confidence interval 1.08-1.33). Thus, our identified loci for rapid kidney function decline may help prioritize therapeutic targets and identify mechanisms and individuals at risk for sustained deterioration of kidney function.